PRESS RELEASE TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn's disease * TiGenix's Cx601 product is currently in Phase 3 in Europe for the treatment of complex perianal fistulas in Crohn's disease * Lonza to manufacture Cx601 product for TiGenix's Phase 3 trial in the US at Lonza's Walkersville, Maryland facility Basel, Switzerland, and Leuven, Belgium, 12 February 2015 - Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix's eASC product, Cx601.
http://ift.tt/1IZa5Gx
http://ift.tt/1IZa5Gx
No comments:
Post a Comment